| name | Budesonide/Formoterol (combination inhaler) |
| classification | Long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination for COPD and Asthma |
| pharmacokinetics | Budesonide is absorbed through the lungs, minimally systemically. Formoterol is rapidly absorbed following inhalation, and has a relatively long duration of action. Detailed pharmacokinetic information is not provided in a simple format, and would require accessing specific prescribing information, including patient-specific factors. |
| suggested dosage | | note | Dosage should be determined by a healthcare professional and individualized based on patient's condition, response, and risk factors. The following is a general guideline and should not be used for self-medication. | | guidelines | | COPD | Initiate with 200 mcg/6 mcg twice daily, as determined by physician. | | Asthma | Initiate with 200 mcg/6 mcg twice daily, as determined by physician. Adjust based on response and control of symptoms. |
|
|
| indications | Used primarily for the management of chronic obstructive pulmonary disease (COPD) and asthma in patients who require both bronchodilator and anti-inflammatory therapy. |
| safety in pregnancy | Limited data exists on the use of budesonide/formoterol during pregnancy. Potential risks to the fetus need to be assessed by a physician in each specific case and weighed against the benefits of the treatment to the mother. Generally, other options should be considered when possible. |
| safety in breastfeeding | Limited data is available for the safety of budesonide/formoterol in breastfeeding mothers. If the use of this drug is deemed necessary, a discussion with a lactation specialist or physician is recommended. Assess potential risks and benefits in each case. |
| side effects | | 1 | Headache | | 2 | Tremor | | 3 | Nausea | | 4 | Dry Mouth | | 5 | Pharyngitis | | 6 | Cough | | 7 | Upper Respiratory Infection | | 8 | Candidiasis (oral) | | 9 | Dysphonia | | 10 | Cardiovascular effects (e.g., tachycardia, palpitations - usually less common with inhaled steroids compared to systemic steroids). | | 11 | Increased risk of pneumonia with high doses or in patients with risk factors for pneumonia. | | 12 | Less common but serious risks (rare): severe allergic reactions, worsening of pre-existing conditions (e.g., heart disease) |
|
| alternatives | | 1 | | | 2 | | drug name | Mometasone/Formoterol | | class details | ICS/LABA combination |
| | 3 | | drug name | Beclomethasone/Formoterol | | class details | ICS/LABA combination |
| | 4 | | drug name | Vilanterol/Fluticasone | | class details | ICS/LABA combination |
|
|
| contraindications | | 1 | Known hypersensitivity to budesonide, formoterol, or any component of the medication | | 2 | Severe heart conditions |
|
| interactions | | 1 | Concurrent use of other bronchodilators | | 2 | Use with other medications like beta-blockers can alter their effectiveness or increase the risk of side effects. | | 3 | Use with other medications that could affect heart rate or blood pressure needs careful consideration. |
|
| warnings and precautions | | 1 | Careful monitoring of blood pressure, pulse, and heart rhythm. | | 2 | Patients with a history of cardiac issues or uncontrolled blood pressure must use extreme caution. | | 3 | Regular monitoring of lung function and symptom control. Avoid use in patients with rare or severe conditions (e.g., uncontrolled heart rhythm). | | 4 | Inform the doctor about all other medications being taken. |
|
| additional informations | This information is for general knowledge and informational purposes only, and does not constitute medical advice. Always consult with a qualified healthcare professional for personalized medical advice, diagnosis, and treatment plans. Do not attempt self-treatment. |
| patient profile | |
